Brief: Neuphoria Therapeutics Says Cash Runway Extends Into Q3 2026 - SEC Filing
20/05/2025 21:21
May 20 (Reuters) - Neuphoria Therapeutics Inc NEUP.O: NEUPHORIA THERAPEUTICS INC - CASH RUNWAY EXTENDS INTO Q3 2026 - SEC FILING NEUPHORIA THERAPEUTICS INC - AFFIRM-1 PHASE 3 TRIAL OF BNC-210 TOPLINE READOUT EXPECTED Q3 2025 - SEC FILING Source text: [ID:n0001213900-25-045970] Further company coverage: NEUP.O ((Reuters.Brief@thomsonreuters.com;))
Recent news on Neuphoria Therapeutics
See all newsBrief: Scancell And Neuphoria Therapeutics Announce Merger Agreement And Financing
NASDAQ RESUMED AT 03:25 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:20 PM
Brief: Neuphoria Therapeutics Confirms Discussions On Potential Acquisition By Scancell
Brief: Neuphoria Responds To Lynx1’S Revised Indication Of Interest At A Reduced Price And Premium